Want to see AU:ALA full AI Analyst Report?
Top Page
Arovella Therapeutics Limited
(Sydney:ALA)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.06
▼(-3.33% Downside)
Action:Reiterated
Date:05/26/26
The score is primarily constrained by weak financial performance (persistent losses and ongoing cash burn), with low leverage and increased equity providing some offset. Technical indicators point to soft momentum and a weaker longer-term trend. Valuation offers limited support due to a negative P/E and no dividend yield.
Positive Factors
Low leverage
Near-zero debt materially reduces financial risk for an R&D‑intensive biotech. Over the next 2–6 months this conservatism lowers interest burdens and bankruptcy risk, preserving optionality to fund trials via equity or partnerships without immediate debt servicing constraints.
Negative Factors
Chronic cash burn
Sustained negative operating and free cash flow means the business cannot self-fund R&D or trials and remains dependent on external financing. Over a 2–6 month horizon this increases dilution and execution risk if financing windows close or terms worsen.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Near-zero debt materially reduces financial risk for an R&D‑intensive biotech. Over the next 2–6 months this conservatism lowers interest burdens and bankruptcy risk, preserving optionality to fund trials via equity or partnerships without immediate debt servicing constraints.
Read all positive factors
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$72.53M
Dividend YieldN/A
Average Volume (3M)1.58M
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue Growth-100.00%
EPS Growth-11.11%
CountryAU
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,208,851,800
10 Day Avg. Volume1,549,358
30 Day Avg. Volume1,578,675
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)5.47
Price to Sales (P/S)806.87
P/FCF Ratio-14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$6.70M
Arovella Therapeutics Limited Business Overview & Revenue Model
Company Description
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several k...
How the Company Makes Money
null...
Arovella Therapeutics Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -3.30M | 136.00K | 17.00K | 405.90K | 295.81K | 257.35K |
| Gross Profit | -3.36M | 136.00K | -25.98K | -3.00M | 88.75K | 34.60K |
| EBITDA | -14.93M | -11.10M | -10.63M | -10.37M | -7.87M | -4.99M |
| Net Income | -7.93M | -7.51M | -8.75M | -10.18M | -8.62M | -5.05M |
Balance Sheet | ||||||
| Total Assets | 20.25M | 21.60M | 13.28M | 5.47M | 9.21M | 10.69M |
| Cash, Cash Equivalents and Short-Term Investments | 19.37M | 20.88M | 12.71M | 5.18M | 6.07M | 6.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 144.80K | 144.80K | 79.23K |
| Total Liabilities | 1.33M | 1.52M | 2.06M | 1.69M | 1.60M | 1.71M |
| Stockholders Equity | 18.92M | 20.08M | 11.23M | 3.78M | 7.62M | 8.98M |
Cash Flow | ||||||
| Free Cash Flow | -6.93M | -7.34M | -7.04M | -6.40M | -6.83M | -4.06M |
| Operating Cash Flow | -6.82M | -6.93M | -6.91M | -6.40M | -6.27M | -3.54M |
| Investing Cash Flow | -122.36K | -432.11K | -179.34K | 95.42K | -566.00K | -514.55K |
| Financing Cash Flow | 14.59M | 15.52M | 14.61M | 5.41M | 6.19M | 9.80M |
Arovella Therapeutics Limited Technical Analysis
Negative
0.06
Price Trends
0.07
Negative
0.07
Negative
0.08
Negative
Market Momentum
>-0.01
Negative
40.01
Neutral
24.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALA, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.01 is Neutral, neither overbought nor oversold. The STOCH value of 24.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ALA.
Arovella Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$89.38M | -8.42 | -62.49% | ― | ― | -13.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$55.00M | -0.92 | -93.08% | ― | 116.02% | 75.56% | |
44 Neutral | AU$72.53M | -8.57 | -40.65% | ― | -100.00% | -11.11% | |
41 Neutral | AU$41.63M | -0.38 | -134.65% | ― | ― | 62.72% | |
41 Neutral | AU$113.04M | -3.27 | 279.21% | ― | ― | -37.23% | |
40 Underperform | AU$67.79M | -0.80 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:ALA
Arovella Therapeutics Limited
0.06
-0.04
-39.00%
AU:IMU
Imugene
0.09
-0.18
-67.92%
AU:IMM
Immutep Ltd
0.05
-0.21
-81.54%
AU:PTX
Prescient Therapeutics Limited
0.09
0.04
100.00%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.01
-50.00%
AU:RCE
Recce Pharmaceuticals Ltd.
0.38
-0.03
-8.54%
Arovella Therapeutics Limited Corporate Events
Arovella Advances CAR-iNKT Programs as First Human Trial Nears
Jul 27, 2026
Arovella Therapeutics reported a transformational June quarter as it moved towards first-in-human clinical evaluation of its lead CAR-iNKT therapy, ALA-101, for relapsed or refractory CD19-positive blood cancers. The company secured ethics and gov...
Arovella options lapse, easing potential shareholder dilution
Jun 30, 2026
Arovella Therapeutics Limited, listed on the ASX under the code ALA, operates in the biotechnology and therapeutics sector. The company focuses on developing medical treatments, positioning itself within the broader life sciences market where capi...
Arovella Therapeutics Seeks ASX Quotation for Additional Shares
Jun 30, 2026
Arovella Therapeutics Limited has applied for quotation of 68,181 new ordinary fully paid shares on the ASX. The securities, to be issued on June 30, 2026 under the ALA ticker, arise from the exercise or conversion of existing options or other con...
Arovella Director Increases Indirect Stake with On-Market Share Purchase
Jun 9, 2026
Arovella Therapeutics has disclosed a change in director David John Williams’ relevant interest in the company’s securities. Through Lawn Views Pty Ltd as trustee for the Angela Williams Family Trust, Williams indirectly acquired 200,0...
Arovella strengthens clinical team ahead of first ALA-101 human trial
Jun 9, 2026
Arovella Therapeutics has bolstered its clinical capabilities ahead of first-in-human trials for its lead CAR iNKT-cell therapy, ALA-101, by appointing renowned cellular immunotherapy expert Professor Cameron Turtle to its Clinical Advisory Board....
Arovella options lapse, trimming potential dilution in capital structure
May 26, 2026
Arovella Therapeutics Limited has notified the market that 2,000,000 listed options under the code ALAAA have lapsed. The options, which were set to expire on various dates at various exercise prices, ceased on May 24, 2026, without being exercise...
Arovella Therapeutics Options Lapse Clarifies Capital Structure
May 8, 2026
Arovella Therapeutics has reported the cessation of 5,668,280 options, identified under the ASX security code ALAAA, after these conditional rights lapsed because their conditions were not met or could no longer be satisfied. The options, which we...
Arovella Therapeutics Reports Director Andrew Nash’s Departure With No Security Interests
May 7, 2026
Arovella Therapeutics Limited has notified the ASX that Andrew Nash ceased to be a director of the company effective 4 May 2026. The final director’s interest notice confirms that Nash held no relevant interests in Arovella securities or rel...
Arovella Highlights Solid-Tumour CAR-iNKT Advances at Global Cell Therapy Meeting
May 7, 2026
Arovella Therapeutics showcased new pre-clinical data on its CLDN18.2-directed CAR-iNKT cell therapy for gastric and pancreatic cancers at the ISCT 2026 cell and gene therapy conference in Dublin. The poster, led by company scientist Dr Clinton He...
Arovella names acting CEO as it heads into key Phase I trial
May 7, 2026
Arovella Therapeutics has appointed Chief Operating Officer Dr Nicole Van Der Weerden as acting chief executive officer following the resignation and termination of former CEO Dr Michael Baker. Her remuneration has been lifted to match her predece...
Arovella Overhauls Board as CEO Resigns, Launches Strategic Review
May 4, 2026
Arovella Therapeutics has undergone a major board overhaul after receiving a shareholder requisition to remove two directors, prompting the resignation of Chief Executive Officer and Managing Director Dr Michael Baker, who will serve a three-month...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.